Bhoomi Mehrotra, MD | Authors

Commentary (Rai/Mehrotra): Current Status of Monoclonal Antibody Therapy for Chronic Lymphocytic Leukemia

February 01, 2003

Drs. Nabhan, Dyer, and Rosenprovide an excellent and comprehensivereview of the therapeuticrole of rituximab (Rituxan)and alemtuzumab (Campath) inchronic lymphocytic leukemia (CLL).We take this opportunity to offer ourcomments concerning these two monoclonalantibodies in CLL.